Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Two doses of JE vaccine · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Three 1 mL doses of Rabies vaccine and two JE vaccine | BIOLOGICAL | Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses) |
| Three 0.5 mL doses of Rabies vaccine and two JE vaccine | BIOLOGICAL | Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses) |
| Three 0.1mL doses of Rabies Vaccine and two JE vaccine | BIOLOGICAL | Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses) |
| Two 0.1mL doses of Rabies vaccine and two JE vaccine | BIOLOGICAL | Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses) |
| Two doses of JE vaccine | BIOLOGICAL | Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses) |
Inclusion Criteria: * Male and female 12-18 months old toddlers if they * are in good health at time of entry into the study * are available for all the visits scheduled in the study * have been granted a written informed consent, signed by their parents Exclusion Criteria: * a history of rabies ...
Two doses of JE vaccine is a Japanese encephalitis vaccine being studied for use in rabies pre-exposure prophylaxis. The investigational vaccine is being evaluated for immunogenicity, safety, and booster response when administered together with a rabies vaccine in toddlers.
Two doses of JE vaccine is being developed by Novartis AG, traded on the New York Stock Exchange under the ticker NVS. The company is conducting clinical research on this investigational Japanese encephalitis vaccine.
Two doses of JE vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 2 trial has been completed.
Two doses of JE vaccine has one completed Phase 2 trial, NCT00694460, which evaluated immunogenicity, safety, and booster response when administered with a rabies vaccine in toddlers. The trial enrolled 200 participants in Thailand and was active-controlled.
No, Two doses of JE vaccine is a Japanese encephalitis vaccine, not a rabies vaccine. In the clinical trial NCT00694460, it was administered concomitantly with a rabies vaccine to evaluate their combined use for pre-exposure prophylaxis against both diseases.